一个METTL3-NFE2L3轴调解瘤干和肺腺癌的进展
Yue Zhao1, Lei Zhang1, Lang Xia1
1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Science advances
|April 18, 2025
概括
肺腺癌的进展涉及抗治疗的癌症干细胞 (CSCs). 向METTL3消除了这些OV6+CSC,克服了耐药性并提高了新辅助治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 癌症干细胞生物学
- 分子瘤学分子瘤学
背景情况:
- 肺腺癌的进展是由癌症干细胞 (CSCs) 驱动的,这些干细胞表现出自我更新和治疗抵抗力.
- CSCs,特别是OV6+瘤细胞,与新辅助化疗和免疫检查点抑制剂组合的反应不佳有关.
- 缺氧和HIF1α信号通路有助于产生OV6+ CSCs.
研究的目的:
- 研究OV6+瘤细胞在肺腺癌进展和治疗耐药性中的作用.
- 阐明管理OV6+CSC的监管机制,重点关注METTL3和NFE2L3.3.
- 评估针对METTL3的治疗潜力及其与标准治疗的结合.
主要方法:
- 对OV6+瘤细胞的鉴定和表征.
- 对低氧和HIF1α参与CSC形成的分析.
- 通过m6A修饰,研究METTL3在稳定NFE2L3mRNA中的作用.
- 对WNT信号通路激活的评估.
- 评估OV6+ CSC对瘤微环境 (TME) 和巨细胞透的影响.
- 测试METTL3抑制 (STM2457) 单独和与西斯普拉丁结合的疗效.
主要成果:
- OV6+瘤细胞具有类似干细胞的特性,并且在病理反应不佳的患者中得到丰富.
- 缺氧和HIF1α驱动OV6+CSCs的形成.
- 通过m6A修饰,METTL3稳定了NFE2L3mRNA,激活了WNT信号,并保持了茎状.
- OV6+ CSCs促进M2巨细胞的透,从而产生一种免疫抑制的TME.
- 向METTL3消除了OV6+CSCs,并抑制了瘤的生长.
- 组合疗法 (STM2457 + cisplatin) 克服了化学抵抗并重塑了TME.
结论:
- OV6+ CSCs是肺腺癌进展和对新辅助疗法的耐药性的关键驱动因素.
- METTL3是OV6+CSCs的关键调节者,提供了一个潜在的治疗点.
- 向METTL3,特别是与化疗相结合,有望提高新辅助治疗的疗效.
相关概念视频
02:17The Tumor Microenvironment
6.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.4K
02:30Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
02:40Cancer Stem Cells and Tumor Maintenance
4.6K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.6K
02:07Tumor Progression
6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
02:53Adaptive Mechanisms in Cancer Cells
5.5K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.5K
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K